

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ALK

1L

2L

UCI 24-192 (Nuvalent)

NVL-655 + Alectinib

Mechanism: ALK inhibitor

Coord: To be determined

Accrual: 0/5

UCI 21-241 (Nuvalent)

NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor

Coord: Keagan Buttigieg

Accrual: 19/25

ADVANCED/METASTATIC

Exon 18

Exon 19 del or L858R



Open to Accrual



Low Accruing



Pending Activation

1L

2L

UCI 24-169
(**BlossomHill**
Therapeutics)
BH-30643
Capsule

Mechanism:
EGFR (Exon 18
and 19 del) or
HER2 TKI
Coord: Celest
Ramirez
Accrual: 5/10

UCI 24-169
(**BlossomHill**
Therapeutic
s)
BH-30643
Capsule

Mechanism:
EGFR (Exon
18 and 19
del) or
HER2 TKI
Coord:
Celest
Ramirez
Accrual:
5/10

UCI 24-181
(**Janssen**
Research &
Development)
Amivantamab +
Lazertinib or
Amivantamab +
platinum-based
chemotherapy
Mechanism:
EGFR TKI
Coord:
Stephanie
Fernandez
Accrual: 1/6

UCI 23-178
BL-B01D1 IV

Mechanism:
EGFR and/or
HER3
bispecific
antibody
Coord: Cassie
Smith
Accrual: 5/10

**UCI 22-
121 (J**
Ints bio)
JIN-A02
Monothera
rapy

Mechani
sm: TKI
Coord:
Cassie
Smith
Accrual:
1/7

**UCI 22-
217(Janssen)**
Amivantamb +
Lazertinib w/ or
without Carbo +
Pemetrexed

Mechanism:
Antibody drug
w/ TKI and
Chemo
Coord: Richard
Chang
Accrual: 5/15

Exon 20

Exon 21

1L

UCI 22-217(Janssen)

Amivantamb + Lazertinib w/ or
without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI
and Chemo
Coord: Richard Chang
Accrual: 5/15

UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism: EGFR
or HER2 TKI
Coord: Celest
Ramirez
Accrual: 5/10

UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism:
EGFR or HER2 TKI
Coord: Celest
Ramirez
Accrual: 5/10

UCI 24-181 (Janssen Research
& Development)

Amivantamab + Lazertinib or
Amivantamab +
platinum-based chemotherapy
Mechanism: EGFR TKI
Coord: Stephanie Fernandez
Accrual: 1/6

2L

Stage 1A / Adjuvant

Open to Accrual

Low Accruing

Pending Activation

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

cMET and EGFR

1L

2L

ADVANCED/METASTATIC

1L

**UCI 23-66 (Boehringer
Ingelheim)**
BI-1810631
Monotherapy

Mechanism: TKI
Coord: Cassie Smith
Accrual: 2/5

2L

UCI 19-64 (Merus N.V.)

Ph I/II Study of MCLA-
128, IgG1 Bispecific
Antibody Targeting
HER2 & HER3, in Pts w/
Solid Tumors

Mechanism: Antibody
Targeting HER2 and
HER3

Coord: Celest Ramirez
Accrual: 8/10

Exon 18

Exon 19

Exon 20

Exon 21

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Celest Ramirez
Accrual: 5/10

UCI 23-178

BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody
Coord: Cassie Smith
Accrual: 5/10

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

KRAS G12C

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
 Coord: Cassie Smith
 Accrual: 3/5

UCI 25-88 (Part A:

Olomorasib w/ Pembro or
 Placebo w/ Pembro. Part B:
 Durvalumab w/ Pembro or
 Placebo w/ Durvalumab)

Mechanism: TKI and Anti-PD-
 1 / Anti-PD-L1
 Coord: TBD
 Accrual: 0/5

2L

UCI 21-53 (Loxo Oncology,
Inc. LOXO-RAS-20001

Mechanism: TKI
 Coord: Jenny Choe
 Accrual: 7/12

UCI 23-116 (RMC-6291
Revolution Medicine)

Mechanism: TKI
 Coordinator: Richard Chang
 Accrual: 0/10

UCI 18-78 (Mirati MRTX-
849)

Mechanism: TKI
 Coord: Celest Ramirez
 24/40

G12A, G12D, G12R, G12S,
G12V
UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
 Coordinator: Jenny Choe
 Accrual: 21/25

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

NRG-LU007

Treatment: (Randomized) Group 1:
Atezolizumab Alone. Group 2:
Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation
Coord: Richard Chang
Accrual: 2/5

UCI 23-169 (Merck V940)

Mechanism: Combo of Pembro with V940
drug to treat Stage II, IIIA, IIIB NCSLC

Coodinator: Cassie Smith

Accrual: 0/10

UCI 25-89 (IBI3009)

Mechanism: Recombinant Anti-DLL3
Monoclonal Antibody-Camptothecin
Derivative Conjugate for Injection

Coodinator: TBD

Accrual: 0/5

ADVANCED/METASTATIC

NTRK 1-3

 Open to Accrual

 Low Accruing

 Pending Activation

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI
Coord: Stephanie Fernandez
Accrual: 17/21

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

1L

2L

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROS1

1L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
Coord: Keagan Buttigieg
Accrual: 10/16

2L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
Coord: Keagan Buttigieg
Accrual: 10/16

UCI 21-108 (AnHeart Therapeutics)

Mechanism: TKI or ROS1 and NTRK
fusion proteins
Coord: Jenny Choe
Accrual: 4/5

Advanced / Metastatic

 Open to Accrual

 Low Accruing

 Pending Activation

1L

UCI 24-83: CB-NK +
Atezolizumab

Mechanism: PD-L1
Coord: Celest Ramirez
Accrual: 0/9

UCI 24-160 Chemo +
Cemiplimab + Agent (a, b, or
none)

Mechanism: PD-L1
Coord: Keagan Buttigieg
Accrual: 0/6

2L

UCI 23-148: CJRB-01 (oral) +
Pembrolizumab

Mechanism: Live
biotherapeutic product +
Pembrolizumab
Coord: Jenny Choe
Accrual: 3/6

 Open to Accrual

 Low Accruing

 Pending Activation

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-197 (TNG456
Monotherapy & Combo w/
Abemaciclib)

Mechanism:
Coord: TBD
Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stefanie Fernandez
Accrual: 5/82

UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA
Coord: Stefanie Fernandez/
Mindy Chen
Accrual: 0/1753

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-75 (CRN09682-191) :
Crinetics Pharmaceuticals

Mechanism: NDC
Coord: TBD
Accrual: 0/15

UCI 24-08 (SPEDOX-6): Dr. Chow
IIT

Mechanism: SPE
Coord: Erin Palmer-Torrison
Accrual: 0/67